{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T14:08:27Z","timestamp":1782310107389,"version":"3.54.5"},"reference-count":73,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T00:00:00Z","timestamp":1747440000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart Lung and Blood Institute","doi-asserted-by":"publisher","award":["R01HL166339"],"award-info":[{"award-number":["R01HL166339"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.blre.2025.101303","type":"journal-article","created":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T05:03:11Z","timestamp":1747717391000},"page":"101303","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Patient-reported outcomes - the missing link to advancing light chain (AL) amyloidosis clinical research"],"prefix":"10.1016","volume":"74","author":[{"given":"Tobias","family":"Dittrich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Weinert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"D'Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"24","key":"10.1016\/j.blre.2025.101303_bb0005","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMra2304088","article-title":"Systemic light chain amyloidosis","volume":"390","author":"Sanchorawala","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2025.101303_bb0010","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2147\/PROM.S399658","article-title":"Health-related quality of life instruments for clinical trials in AL amyloidosis: report from the amyloidosis forum HRQOL working group","volume":"14","author":"Rizio","year":"2023","journal-title":"Patient Relat Outcome Meas"},{"key":"10.1016\/j.blre.2025.101303_bb0015","article-title":"Cardiac biomarkers and health-related quality of life in patients with light chain (AL) amyloidosis","author":"McCausland","year":"2018","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.blre.2025.101303_bb0020","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/bjh.14889","article-title":"A longitudinal evaluation of health-related quality of life in patients with AL amyloidosis: associations with health outcomes over time","volume":"179","author":"Sanchorawala","year":"2017","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.blre.2025.101303_bb0025","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-021-00412-8","article-title":"Changes in patient-reported outcomes in light chain amyloidosis in the first year after diagnosis and relationship to NT-proBNP change","volume":"11","author":"D\u2019Souza","year":"2021","journal-title":"Blood Cancer J"},{"issue":"11","key":"10.1016\/j.blre.2025.101303_bb0030","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1016\/j.mayocp.2019.04.005","article-title":"Patient reported outcomes have arrived: a practical overview for clinicians in using patient reported outcomes in oncology","volume":"94","author":"Warsame","year":"2019","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"10.1016\/j.blre.2025.101303_bb0035","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/jama.2017.7156","article-title":"Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment","volume":"318","author":"Basch","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.blre.2025.101303_bb0040","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1200\/CCI.20.00081","article-title":"Clinical utility and user perceptions of a digital system for electronic patient-reported symptom monitoring during routine Cancer care: findings from the PRO-TECT trial","volume":"4","author":"Basch","year":"2020","journal-title":"JCO Clin Cancer Inform"},{"issue":"10","key":"10.1016\/j.blre.2025.101303_bb0045","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.4065\/82.10.1244","article-title":"Precision of health-related quality-of-life data compared with other clinical measures","volume":"82","author":"Hahn","year":"2007","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"10.1016\/j.blre.2025.101303_bb0050","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13023-018-0810-x","article-title":"Patient reported outcome measures in rare diseases: a narrative review","volume":"13","author":"Slade","year":"2018","journal-title":"Orphanet J Rare Dis"},{"issue":"15","key":"10.1016\/j.blre.2025.101303_bb0055","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1007\/s11606-023-08380-4","article-title":"Health-related quality of life scores and values as predictors of mortality: a scoping review","volume":"38","author":"Nevarez-Flores","year":"2023","journal-title":"J Gen Intern Med"},{"issue":"8","key":"10.1016\/j.blre.2025.101303_bb0060","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1200\/JCO.2007.13.3439","article-title":"The prognostic significance of patient-reported outcomes in cancer clinical trials","volume":"26","author":"Gotay","year":"2008","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.blre.2025.101303_bb0065","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1007\/s11136-023-03591-y","article-title":"Baseline functioning scales of EORTC QLQ-C30 predict overall survival in patients with gastrointestinal cancer: a meta-analysis","volume":"33","author":"Zang","year":"2024","journal-title":"Qual Life Res"},{"issue":"2","key":"10.1016\/j.blre.2025.101303_bb0070","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/cncr.28382","article-title":"A global analysis of multitrial data investigating quality of life and symptoms as prognostic factors for survival in different tumor sites","volume":"120","author":"Quinten","year":"2014","journal-title":"Cancer"},{"issue":"34","key":"10.1016\/j.blre.2025.101303_bb0075","doi-asserted-by":"crossref","first-page":"5816","DOI":"10.1200\/JCO.2009.23.7420","article-title":"Quality of life supersedes the classic prognosticators for long-term survival in locally advanced non-small-cell lung cancer: an analysis of RTOG 9801","volume":"27","author":"Movsas","year":"2009","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.blre.2025.101303_bb0080","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12885-016-2995-5","article-title":"Prognostic values of EORTC QLQ-C30 and QLQ-HCC18 index-scores in patients with hepatocellular carcinoma - clinical application of health-related quality-of-life data","volume":"17","author":"Li","year":"2017","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.blre.2025.101303_bb0085","doi-asserted-by":"crossref","first-page":"e722","DOI":"10.1634\/theoncologist.2019-0348","article-title":"The EORTC QLQ-C30 summary score as prognostic factor for survival of patients with Cancer in the \u201creal-world\u201d: results from the population-based PROFILES registry","volume":"25","author":"Husson","year":"2020","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.blre.2025.101303_bb0090","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1017\/S1478951509990216","article-title":"Quality of life measures (EORTC QLQ-C30 and SF-36) as predictors of survival in palliative colorectal and lung cancer patients","volume":"7","author":"Grande","year":"2009","journal-title":"Palliat Support Care"},{"issue":"9","key":"10.1016\/j.blre.2025.101303_bb0095","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/S1470-2045(09)70200-1","article-title":"Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials","volume":"10","author":"Quinten","year":"2009","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.blre.2025.101303_bb0100","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"10.1016\/j.blre.2025.101303_bb0105","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1007\/s11136-021-02943-w","article-title":"Development of a conceptual model of patient-reported outcomes in light chain amyloidosis: a qualitative study","volume":"31","author":"D\u2019Souza","year":"2022","journal-title":"Qual Life Res"},{"issue":"4","key":"10.1016\/j.blre.2025.101303_bb0110","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3109\/13506129.2015.1102131","article-title":"The patient\u2019s perspective on the symptom and everyday life impact of AL amyloidosis","volume":"22","author":"Lin","year":"2015","journal-title":"Amyloid"},{"key":"10.1016\/j.blre.2025.101303_bb0115","first-page":"1","article-title":"The use of PROMIS patient-reported outcomes (PROs) to inform light chain (AL) amyloid disease severity at diagnosis","author":"D\u2019Souza","year":"2020","journal-title":"Amyloid"},{"issue":"6","key":"10.1016\/j.blre.2025.101303_bb0120","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1007\/s11136-023-03354-9","article-title":"A cross-sectional study of patient-reported outcomes and symptom burden using PROMIS and PRO-CTCAE measures in light chain amyloidosis","volume":"32","author":"D\u2019Souza","year":"2023","journal-title":"Qual Life Res"},{"issue":"3","key":"10.1016\/j.blre.2025.101303_bb0125","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/bjh.18645","article-title":"Linking changes in quality of life to haematologic response and survival in systemic immunoglobulin light-chain amyloidosis","volume":"201","author":"Cohen","year":"2023","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.blre.2025.101303_bb0130","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.3324\/haematol.2018.205336","article-title":"Performance analysis of AL amyloidosis cardiac biomarker staging systems with special focus on renal failure and atrial arrhythmia","volume":"104","author":"Dittrich","year":"2019","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.blre.2025.101303_bb0135","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements","volume":"30","author":"Kumar","year":"2012","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.blre.2025.101303_bb0140","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1182\/blood-2004-01-0089","article-title":"Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation","volume":"104","author":"Seldin","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101303_bb0145","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.24676","article-title":"Hematology patient reported symptom screen to assess quality of life for AL amyloidosis","author":"Warsame","year":"2017","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.blre.2025.101303_bb0150","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/ejh.14036","article-title":"Differences in patient-reported outcomes (PROs) by disease severity in light chain (AL) amyloidosis","volume":"111","author":"D\u2019Souza","year":"2023","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2025.101303_bb0155","doi-asserted-by":"crossref","DOI":"10.1007\/s41669-019-0122-7","article-title":"Associations between health-related quality of life and self-reported emergency room department visits and inpatient hospitalizations: insights from a secondary data analysis of patients with light-chain (AL) amyloidosis","author":"McCausland","year":"2019","journal-title":"Pharmacoecon Open"},{"issue":"1","key":"10.1016\/j.blre.2025.101303_bb0160","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1093\/annonc\/mdx757","article-title":"European Society for Medical Oncology (ESMO) position paper on supportive and palliative care","volume":"29","author":"Jordan","year":"2018","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.blre.2025.101303_bb0165","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/annonc\/mdy524","article-title":"Patient-reported outcomes (PROs) as a routine measure for cancer inpatients: the final missing piece of the puzzle?","volume":"30","author":"Brandt","year":"2019","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.blre.2025.101303_bb0170","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.122.009677","article-title":"Evaluating the implementation of patient-reported outcomes in heart failure clinic: a qualitative assessment","volume":"16","author":"Brown-Johnson","year":"2023","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.blre.2025.101303_bb0175","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s41687-018-0061-6","article-title":"How do patient reported outcome measures (PROMs) support clinician-patient communication and patient care? A realist synthesis","volume":"2","author":"Greenhalgh","year":"2018","journal-title":"J Patient Rep Outcomes"},{"issue":"23","key":"10.1016\/j.blre.2025.101303_bb0180","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1093\/jnci\/djp386","article-title":"Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes","volume":"101","author":"Basch","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.blre.2025.101303_bb0185","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1200\/EDBK_200383","article-title":"Implementation of patient-reported outcomes in routine medical care","volume":"38","author":"Basch","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"8","key":"10.1016\/j.blre.2025.101303_bb0190","first-page":"530","article-title":"Agreement between patient-reported symptoms and their documentation in the medical record","volume":"14","author":"Pakhomov","year":"2008","journal-title":"Am J Manag Care"},{"issue":"11","key":"10.1016\/j.blre.2025.101303_bb0195","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S1470-2045(06)70910-X","article-title":"Patient versus clinician symptom reporting using the National Cancer Institute common terminology criteria for adverse events: results of a questionnaire-based study","volume":"7","author":"Basch","year":"2006","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.blre.2025.101303_bb0200","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1056\/NEJMp1702978","article-title":"Patient-reported outcomes - are they living up to their potential?","volume":"377","author":"Baumhauer","year":"2017","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.blre.2025.101303_bb0205","first-page":"3941","article-title":"Do drugs offering only PFS maintain quality of life sufficiently from a patient\u2019s perspective? Results from AVALPROFS (assessing the \u2018VALue\u2019 to patients of PROgression free survival) study","volume":"26","author":"Jenkins","year":"2018","journal-title":"Support Care Cancer"},{"issue":"24","key":"10.1016\/j.blre.2025.101303_bb0210","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15245763","article-title":"Self-reported baseline quality of life mirrors treatment-specific characteristics of cancer patients","volume":"15","author":"Thronicke","year":"2023","journal-title":"Cancers"},{"issue":"8","key":"10.1016\/j.blre.2025.101303_bb0215","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1001\/jamaoncol.2016.6749","article-title":"Feasibility assessment of patient reporting of symptomatic adverse events in multicenter cancer clinical trials","volume":"3","author":"Basch","year":"2017","journal-title":"JAMA Oncol"},{"issue":"24","key":"10.1016\/j.blre.2025.101303_bb0220","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1001\/jama.2022.9265","article-title":"Effect of electronic symptom monitoring on patient-reported outcomes among patients with metastatic cancer: a randomized clinical trial","volume":"327","author":"Basch","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.blre.2025.101303_bb0225","article-title":"ENABLE: App-based digital capture and intervention of patientreported quality of life, adverse events, and treatment satisfaction in breast cancer - study protocol for a randomized controlled trial","author":"Deutsch","year":"2025","journal-title":"JMIR Res Protocols"},{"issue":"6","key":"10.1016\/j.blre.2025.101303_bb0230","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.121.009038","article-title":"Proposed cardiac end points for clinical trials in immunoglobulin light chain amyloidosis: report from the amyloidosis forum cardiac working group","volume":"15","author":"Maurer","year":"2022","journal-title":"Circ Heart Fail"},{"issue":"2","key":"10.1016\/j.blre.2025.101303_bb0235","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.bbmt.2015.07.036","article-title":"Higher stem cell dose infusion after intensive chemotherapy does not improve symptom burden in older patients with multiple myeloma and amyloidosis","volume":"22","author":"Shah","year":"2016","journal-title":"Biol Blood Marrow Transpl"},{"key":"10.1016\/j.blre.2025.101303_bb0240","article-title":"Adjuvant doxycycline to enhance anti-amyloid effects: results from the dual phase 2 trial","volume":"23","author":"D\u2019Souza","year":"2020","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.blre.2025.101303_bb0245","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.26536","article-title":"Health-related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone +\/\u2212 daratumumab: Results from the ANDROMEDA study","author":"Sanchorawala","year":"2022","journal-title":"Am J Hematol"},{"issue":"14","key":"10.1016\/j.blre.2025.101303_bb0250","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood.2022019406","article-title":"Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial","volume":"142","author":"Gertz","year":"2023","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2025.101303_bb0255","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1002\/ajh.26866","article-title":"Quality of life and symptoms among patients with relapsed\/refractory AL amyloidosis treated with ixazomib-dexamethasone versus physician\u2019s choice","volume":"98","author":"Sanchorawala","year":"2023","journal-title":"Am J Hematol"},{"issue":"28","key":"10.1016\/j.blre.2025.101303_bb0260","doi-asserted-by":"crossref","first-page":"3252","DOI":"10.1200\/JCO.20.01285","article-title":"Bortezomib, melphalan, and dexamethasone for light-chain amyloidosis","volume":"38","author":"Kastritis","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2025.101303_bb0265","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2147\/PROM.S146849","article-title":"Psychometric validation of the SF-36 health survey in light chain amyloidosis: results from community-based and clinic-based samples","volume":"8","author":"White","year":"2017","journal-title":"Patient Relat Outcome Meas"},{"issue":"1","key":"10.1016\/j.blre.2025.101303_bb0270","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2025.101303_bb0275","author":"FDA"},{"key":"10.1016\/j.blre.2025.101303_bb0280","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.885910","article-title":"Defining a standard set of patient-reported outcomes for patients with advanced ovarian Cancer","volume":"12","author":"Escudero-Vilaplana","year":"2022","journal-title":"Front Oncol"},{"issue":"10","key":"10.1016\/j.blre.2025.101303_bb0285","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0076625","article-title":"Inconsistencies in quality of life data collection in clinical trials: a potential source of bias? Interviews with research nurses and trialists","volume":"8","author":"Kyte","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.blre.2025.101303_bb0290","doi-asserted-by":"crossref","DOI":"10.1038\/s41746-022-00736-0","article-title":"Characterization of multi-domain postoperative recovery trajectories after cardiac surgery using a digital platform","volume":"5","author":"Mori","year":"2022","journal-title":"NPJ Digit Med"},{"key":"10.1016\/j.blre.2025.101303_bb0295","doi-asserted-by":"crossref","DOI":"10.1177\/21514593251331539","article-title":"Does patient health literacy affect patient reported outcome measure completion method in Orthopaedic patients?","volume":"16","author":"Trotter","year":"2025","journal-title":"Geriatr Orthop Surg Rehabil"},{"issue":"6","key":"10.1016\/j.blre.2025.101303_bb0300","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1007\/s11136-021-02999-8","article-title":"Patient-level barriers and facilitators to completion of patient-reported outcomes measures","volume":"31","author":"Long","year":"2022","journal-title":"Qual Life Res"},{"issue":"4","key":"10.1016\/j.blre.2025.101303_bb0305","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/j.1524-4733.2008.00470.x","article-title":"Recommendations on evidence needed to support measurement equivalence between electronic and paper-based patient-reported outcome (PRO) measures: ISPOR ePRO good research practices task force report","volume":"12","author":"Coons","year":"2009","journal-title":"Value Health"},{"issue":"2","key":"10.1016\/j.blre.2025.101303_bb0310","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1524-4733.2007.00231.x","article-title":"Equivalence of electronic and paper-and-pencil administration of patient-reported outcome measures: a meta-analytic review","volume":"11","author":"Gwaltney","year":"2008","journal-title":"Value Health"},{"issue":"8","key":"10.1016\/j.blre.2025.101303_bb0315","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1007\/s11136-015-0937-3","article-title":"Equivalence of electronic and paper-based patient-reported outcome measures","volume":"24","author":"Campbell","year":"2015","journal-title":"Qual Life Res"},{"issue":"7","key":"10.1016\/j.blre.2025.101303_bb0320","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1007\/s11136-018-1851-2","article-title":"A meta-analytic review of measurement equivalence study findings of the SF-36(R) and SF-12(R) health surveys across electronic modes compared to paper administration","volume":"27","author":"White","year":"2018","journal-title":"Qual Life Res"},{"issue":"1","key":"10.1016\/j.blre.2025.101303_bb0325","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12969-021-00551-z","article-title":"Electronic forms for patient reported outcome measures (PROMs) are an effective, time-efficient, and cost-minimizing alternative to paper forms","volume":"19","author":"Yu","year":"2021","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.blre.2025.101303_bb0330","doi-asserted-by":"crossref","DOI":"10.1038\/sdata.2016.18","article-title":"The FAIR Guiding Principles for scientific data management and stewardship","volume":"3","author":"Wilkinson","year":"2016","journal-title":"Sci Data"},{"issue":"1","key":"10.1016\/j.blre.2025.101303_bb0335","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41746-023-00994-6","article-title":"Next-generation study databases require FAIR, EHR-integrated, and scalable electronic data capture for medical documentation and decision support","volume":"7","author":"Dugas","year":"2024","journal-title":"NPJ Digit Med"},{"key":"10.1016\/j.blre.2025.101303_bb0340","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2147\/PROM.S156279","article-title":"The importance of patient-reported outcomes in clinical trials and strategies for future optimization","volume":"9","author":"Mercieca-Bebber","year":"2018","journal-title":"Patient Relat Outcome Meas"},{"issue":"8","key":"10.1016\/j.blre.2025.101303_bb0345","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1001\/jama.2013.879","article-title":"Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension","volume":"309","author":"Calvert","year":"2013","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.blre.2025.101303_bb0350","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1111\/ejh.14183","article-title":"Development and initial validation of the AL-PROfile patient-reported outcome measure in light chain (AL) amyloidosis","volume":"112","author":"D\u2019Souza","year":"2024","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2025.101303_bib351","unstructured":"Medidata Solutions [Internet]. [cited 2024 Oct 27]. Medidata | Unified Life Science Platform. Available from: https:\/\/www.medidata.com\/en\/."},{"key":"10.1016\/j.blre.2025.101303_bib352","unstructured":"Oracle Health [Internet]. [cited 2024 Oct 27]. Available from: https:\/\/www.oracle.com\/health\/."},{"key":"10.1016\/j.blre.2025.101303_bib353","unstructured":"WCG [Internet]. [cited 2024 Oct 27]. eResearch CTMS. Available from: https:\/\/www.wcgclinical.com\/technologies\/eresearch-ctms\/."}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X25000487?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X25000487?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T17:37:38Z","timestamp":1766079458000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X25000487"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":73,"alternative-id":["S0268960X25000487"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2025.101303","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient-reported outcomes - the missing link to advancing light chain (AL) amyloidosis clinical research","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2025.101303","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101303"}}